Drugs / ISIS-PTP1BRx
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01918865 | Aug 2013 → Oct 2014 | obesity disorder, type 2 diabetes mellitus | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2015-02-03 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports Data From Phase 2 Study of ISIS-PTP1B Rx in Patients With Type 2 Diabetes ionis.com ↗
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today top-line results from a Phase 2 study of ISIS-PTP1BRx in patients with type 2 diabetes. |
| 2012-12-07 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders ionis.com ↗
In the Phase 1 study of ISIS-PTP1BRx in obese healthy volunteers, Isis observed encouraging data in measures of insulin sensitivity and in a biomarker associated with weight loss. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-02-03 | Ionis Pharmaceuticals | Isis Pharmaceuticals Reports Data From Phase 2 Study of ISIS-PTP1B Rx in Patients With Type 2 Diabetes ionis.com ↗ |
| 2012-12-07 | Ionis Pharmaceuticals | Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders ionis.com ↗ |
| 2011-07-21 | Ionis Pharmaceuticals | Isis Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes ionis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS-PTP1BRx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01918865 ↗ |
| Action | Inhibit | “antisense inhibitor of protein tyrosine phosphatase 1B” PMID 29439147 ↗ Feb 2018 |
| Modality | Antisense oligonucleotide | “a second-generation 2'-O-methoxyethyl antisense inhibitor” PMID 29439147 ↗ Feb 2018 |